8-K: PepGen Reports Strong DM1 Trial Data, Extends Cash Runway

PepGen Inc. announced positive third-quarter 2025 financial results and significant clinical progress for its lead DM1 candidate, PGN-EDODM1, extending its cash runway into the second half of 2027.

Summary

• Reported Q3 2025 financial results and recent corporate highlights.
• The FREEDOM-DM1 15 mg/kg cohort demonstrated a mean splicing correction of 53.7%, which is the highest reported to date in Myotonic Dystrophy Type 1 (DM1) patients, with all patients showing improvement.
• PGN-EDODM1 was generally well tolerated at the 15 mg/kg dose.
• All patients in the FREEDOM2-DM1 5 mg/kg cohort have been enrolled and received at least one dose, with results on track for Q1 2026.
• Dosing for the FREEDOM2-DM1 10 mg/kg cohort is expected to begin in Q1 2026, with results anticipated in 2H 2026.
• Closed a $115 million underwritten public offering in September 2025, extending the cash runway into the second half of 2027.
• Cash, cash equivalents, and marketable securities totaled $163.7 million as of September 30, 2025.
• Net loss for Q3 2025 was $18.0 million, or $(0.52) per share, an improvement from $21.4 million, or $(0.66) per share, in Q3 2024.

Sentiment

Score: 8

Explanation: The filing presents very strong positive clinical data for its lead candidate, PGN-EDODM1, with unprecedented splicing correction results. This, combined with a successful capital raise extending the cash runway, indicates significant progress and improved financial stability for a clinical-stage biotech. The reduction in net loss and operating expenses also contributes to a positive sentiment.

Positives

• Achieved 53.7% mean splicing correction in the FREEDOM-DM1 15 mg/kg cohort, the highest reported to date in DM1 patients.
• PGN-EDODM1 was generally well tolerated at the 15 mg/kg dose.
• All patients enrolled and dosed in the FREEDOM2-DM1 5 mg/kg cohort, remaining on track for a Q1 2026 readout.
• Successfully raised $115 million through a public offering in September 2025.
• Extended the company's cash runway into the second half of 2027.
• Reduced net loss to $18.0 million in Q3 2025 from $21.4 million in Q3 2024.
• Decreased Research and Development expenses to $13.4 million in Q3 2025 from $17.7 million in Q3 2024.
• Decreased General and Administrative expenses to $5.2 million in Q3 2025 from $5.4 million in Q3 2024.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for product candidates, including PGN-EDODM1.
• Inability to enroll patients in clinical trials, including FREEDOM2.
• Interpretation of clinical and preclinical study results may be incorrect, or anticipated therapeutic activity levels may not be observed in clinical testing.
• Product candidates, including PGN-EDODM1, may not be safe and effective or demonstrate safety and efficacy in clinical trials.
• Adverse outcomes from regulatory interactions, including delays in regulatory review, clearance, or approval, or regulatory feedback requiring modifications to development programs.
• Changes in the regulatory framework that are beyond the company's control.
• Inability to obtain, maintain, and protect intellectual property.
• Inability to enforce patents against infringers and defend the patent portfolio against third-party challenges.
• Competition from others developing therapies for indications the company is pursuing.
• Unexpected increases in expenses associated with development activities or other events that adversely impact financial resources and cash runway.
• Dependence on third parties for some or all aspects of product manufacturing, research, and preclinical and clinical testing.

Future Outlook

PepGen anticipates reporting results from the FREEDOM2-DM1 5 mg/kg cohort in the first quarter of 2026 and initiating dosing for the 10 mg/kg cohort during the same quarter, with results expected in the second half of 2026. The company projects its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2027.

Management Comments

• "This quarter was defined by the strong results from the 15 mg/kg cohort of our FREEDOM study, which showed unprecedented levels of splicing correction following a single dose."
• "With the key objectives of the FREEDOM study achieved, we are carrying this momentum forward as we advance our multiple ascending dose trial, FREEDOM2."
• "Because mis-splicing is the underlying cause of DM1, we believe that the high levels of splicing correction we achieved have the potential to translate into meaningful functional improvements across key outcome measures, including myotonia and muscle weakness, over time; and we are eager to demonstrate this in FREEDOM2."
• "Bolstered by our recent financing, we are now well positioned to advance FREEDOM2 and further validate the potential of PGN-EDODM1 to become a best-in-class treatment for individuals living with DM1."
• "We look forward to sharing data from the 5 mg/kg multi-dose cohort in the first quarter of next year."

Industry Context

The development of PGN-EDODM1, an oligonucleotide therapy leveraging PepGen's Enhanced Delivery Oligonucleotide (EDO) platform, addresses Myotonic Dystrophy Type 1 (DM1), a severe neuromuscular disease with significant unmet medical needs. The reported 'highest mean splicing correction to date' positions PepGen as a potential leader in developing therapies that target the root cause of DM1, distinguishing its approach from modalities relying on knockdown or degradation of DMPK transcripts.

Comparison to Industry Standards

• The FREEDOM-DM1 15 mg/kg cohort demonstrated a mean splicing correction of 53.7%, which is stated as "substantially higher than any previously reported splicing correction in DM1 patients."
• PGN-EDODM1's mechanism of action, designed to restore MBNL1 splicing function without degrading DMPK transcripts, is presented as having "considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts."
• The company aims for PGN-EDODM1 to become a "best-in-class treatment" for DM1.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, extended cash runway, and reduced net loss, potentially increasing investor confidence and share value.
• Patients (DM1): Significant positive impact as PGN-EDODM1 shows promising efficacy with "highest reported" splicing correction, offering hope for a "best-in-class" treatment for a severe disease.
• Employees: Increased job security and stability due to extended cash runway and positive program momentum.
• Creditors/Suppliers: Improved financial health and extended runway reduce immediate financial risk.

Next Steps

• Report results from the FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
• Initiate dosing in the FREEDOM2-DM1 10 mg/kg cohort in Q1 2026.
• Report results from the FREEDOM2-DM1 10 mg/kg cohort in 2H 2026.
• Further validate the potential of PGN-EDODM1 to become a best-in-class treatment for DM1.

Key Dates

Recommendation

The filing details unprecedented positive clinical data for PGN-EDODM1 in Myotonic Dystrophy Type 1, demonstrating the highest mean splicing correction reported to date. This strong efficacy signal, coupled with a well-tolerated safety profile and a successful $115 million capital raise that extends the cash runway into the second half of 2027, significantly de-risks the company's near-term operations and enhances its potential for future success. The progress in advancing the FREEDOM2 trial and the potential for a 'best-in-class' treatment for a severe unmet medical need make PepGen an attractive investment for long-term growth, despite the inherent risks of a clinical-stage biotech.

Keywords

PepGen, PGN-EDODM1, Myotonic Dystrophy Type 1, DM1, Oligonucleotide Therapy, Clinical Trial, FREEDOM-DM1, FREEDOM2-DM1, Splicing Correction, Biotechnology, Drug Development, Rare Disease, Neuromuscular Disease, SEC Filing, Financial Results, Cash Runway, Public Offering